Get started

MRNA

Moderna | MRNA | Short, Falling WedgeModerna ( NASDAQ:MRNA ) is in a falling wedge with no signs of escaping (yet). While it may have a small pop if there is good company news, the COVID-19 buying spree may be truly over. The COVID-19 pandemic will soon be an endemic and the market may shift fully away from "COVID-19 tickers". Insiders continue to dump shares. Since the start of 2022, insiders have sold $57 million worth of shares. $10 million of this total in the past 13 days (source: OpenInsider). I anticipate Moderna to be below $100 in the coming months if it doesn't break the falling wedge's resistance.
NASDAQ:MRNAShort
by WorthlessViews
Moderna: Sell the Break Setup Moderna - Short Term - We look to Sell a break of 137.05 (stop at 147.24) A move through bespoke support at 140.00 and we look for extended losses. Closed below the 20-day EMA. The primary trend remains bearish. Our overall sentiment remains bearish looking for lower levels. We look to set shorts in the early trade. Our profit targets will be 108.99 and 103.50 Resistance: 150.00 / 170.00 / 200.00 Support: 140.00 / 120.00 / 100.00 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
NASDAQ:MRNAShort
by Saxo
2
PFE still lower to go. Pfizer looks to test $50, and possibly the gap around 46~ if things get really ugly. Omicron is looking really promising as granting significant immunity after infection, which should reduce demand for further vaccinations. These vaccines companies have YEARS of covid priced into their stocks... Short side is getting a bit long in the tooth for new entries, however I am still holding 2/3rds of my puts across the board for these plays. We posted our short thesis in another thread www.tradingview.com
NYSE:PFEShort
by WLinvestment
4
Potential Double Bottom On Moderna (NASDAQ: $MRNA) 🧬Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, Metagenomi, Inc., and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd.; Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group; Aldevron, LLC; Institute for Life Changing Medicines; and AbCellera Biologics Inc. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
NASDAQ:MRNALong
by RedHotStocks
Covid could be endemic within weeks with Omicron. MRNA? PFE?While we need another week~ to confirm, many leading scientists are pointing to death rates anywhere from 30% to 90% lower with Omicron. Yes, it's still problematic but there's hope for the first time in a long time. What happens is Omicron becomes the dominant variant and the majority of people have minimal symptoms? We could see a DRASTIC repricing in some of the vaccine stocks, particularily MRNA. Fair value on MRNA is likely <$100. If we can't reclaim $315, I think we will see $180 and possible $150 within weeks. I bought some OTM puts for a lotto play :p.
NASDAQ:MRNAShort
by WLinvestment
9
NEXCF: Downtrend breakout Initial PT $8NEXCF has just broken its long downtrend line which is usually due to some fundamental change in the company and trajectory of cash flow. The company has rebranded more into an AR 3D marketing company. They still have their digital edtech app and online conferencing but the reposition was a wise one considering the pandemic is coming to an end and many employees will be returning to work. If you noticed this past week the largest losers in the Nasdaq were pandemic plays such as Zoom (ZM) and Moderna (MRNA). The business pivot will play a crucial role into the burgeoning AR space which is becoming a greater theme in 2022. Fib extension target in the $12 range but no promises we get there - first target will be $8.
OTC:NEXCFLong
by ich1baN
MRNA Support Bounce Weekly Option PlayDescription Today saw MRNA performing a high-volume bounce from the 224 support line which initiated the start of what appears to be a rough Descending Triangle. I am bearish on MRNA for the longer term, but expect this upward move to continue throughout the week, along with the rest of the indexes that have seen a strong bounce today. At the least, I am expecting a move up to touch the converging 50/200D EMA lines, and looking for a max expected move in the time frame of one week up to the higher strike @ 257.5 to take profits. If the move is strong enough, we will let the position trade late into Friday to allow the spread to widen out to max profit potential, but I am willing to close the position early. Using a call credit spread to reduce the price and due to expectations of an IV decrease throughout the week. Call Credit Spread Levels on Chart SL: 224 PT : 257.5 *Stops based off underlying stock price, not mark to market loss The Trade BUY 1/14 235C SELL 1/14 257.5C R/R & Breakevens vary on fill. If you can afford it, and have the conviction in the direction of MRNA, I would opt for a Call in conjunction with a Put Credit Spread. This will allow you realize profits much sooner in the case of a meteoric rise such as the one that occurred from 18 - 26 November. Manage Risk Only invest what you are willing to lose
NASDAQ:MRNALong
by BarnardR
Covid strike back AGAINThe new covid strain "Omicorn" is spreading quickly all over the world. The obvious play for covid is investing in vaccines. PFE all time high is $61, currently its at $58. Where MRNA all time high is $500, currently its $248. Thats 50% discount from ATH. Technical: There is a clear strong support trend line that we're bouncing off. BlueWave is setting up to give a green dot buy signal (bottom wave green dot is the strongest of signals on bigger time frames)
NASDAQ:MRNALong
by MoonBets
6
$ARCT is a BUY nowArcturus Therapeutics Holdings Inc. $ARCT is set to be EBITDA positive in 2022 with a massive change in its revenue from 24.05M in 2021 to 326.44M in 2022. This is 12.57x increase in revenue. These numbers are estimates, but even with a large error margin we should see a drastic change in the price. Moreover, the decline from ATH was 80% and the price has been in a sideways movement after it bottomed. With today's strong breakout of the descending channel, I am expecting the price to start its rise up to the upper band of the range-bound around $63. The long-term targets should be a lot higher. The breakout setup entry provides us with an awesome +3 Reward/Risk. A tighter stop loss order can even make it a lot better. A late entry at current prices provides 1.8-2.0 which is still a good ratio. BioTech stocks are risky and volatile. This is not financial advice. DYODD
NASDAQ:ARCTLong
by IboProtrader
Moderna Analysis 11.12.2021Hello Traders, welcome to this free and educational analysis. I am going to explain where I think this asset is going to go over the next few days and weeks and where I would look for trading opportunities. If you have any questions or suggestions which asset I should analyse tomorrow, please leave a comment below. If you enjoyed this analysis, I would definitely appreciate it, if you smash that like button and maybe consider following my channel. Thank you for watching and I will see you tomorrow!
NASDAQ:MRNA
by basictradingtv
100